Merck KGaA, Darmstadt, Germany, and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
- FDA orphan drug designation for avelumab an important regulatory milestone
- Alliance between Merck KGaA, Darmstadt, Germany, and Pfizer continues to dedicate significant resources to accelerate clinical program for high-priority investigational anti-PD-L1
Public Company Information:
2. Kaae J et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst 2010;102(11):793–801.
3. Lemos BD et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 2010;63(5):751–761.